Non-Alkolik Yağlı Karaciğer Hastalığı ve Kafein

Non-alkolik yağlı karaciğer hastalığı (NAYKH), viral enfeksiyon, önemli miktarda alkol alımı (kadınlar için 10 g/gün, erkekler için 20 g/gün) ve karaciğer hastalığının herhangi bir etiyolojisi olmaksızın hepatositlerde %5’in üzerinde yağ birikimi olarak tanımlanır. Non-alkolik yağlı karaciğer hastalığının prevalansı, obezite, insülin direnci ve metabolik sendrom (MetS)’un diğer bileşenleri ile doğru orantılıdır. Karaciğer dışında komplikasyonlara da neden olan NAYKH’ın gelişimi, ilerlemesi ve tedavisi üzerine yapılan çalışmalar artış göstermiştir. Yakın zamanda yapılan çalışmalarda kahve tüketiminin karaciğeri koruyucu etkisi olduğu gösterilmiştir. Kahvenin içeriğindeki kafeinin, hepatosit ve hepatik stellat hücrelerde (HSC) çeşitli mekanizmalarla anti-fibrotik etki gösterdiği belirtilmektedir. Bu derlemenin amacı, NAYKH’da kafeinin koruyucu etkisini güncel literatüre dayanarak incelemektir.

Non-Alcoholic Fatty Liver Disease and Caffeine

Non-alcoholic fatty liver disease (NAFLD) is defined as over 5% lipid accumulation in hepatocytes without viral infection, a significant amount of alcohol intake (10 g/day for women, 20 g/day for men) and any other etiology of liver disease. Non-alcoholic fatty liver disease prevalence is directly proportional to obesity, insulin resistance and other components of the metabolic syndrome (MetS). Research on development, progression and treatment of NAFLD, which also causes complications outside of the liver, have increased. Recent research have shown that coffee consumption has a protective effect on the liver. It has been reported that caffeine from coffee has anti-fibrotic activity with various mechanisms in hepatocytes and hepatic stellate cells (HSC). The purpose of this review is to examine the protective effects of caffeine on NAFLD based on current literature.

PDF

___

Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013;58(3):593-608.
Buzzetti E, Pinzani M, Tsochatzis EA. The multiple- hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016;65(8):1038-1048.
Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62(1):47-64.
Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med2017;15(1):45.
AnguloP.Nonalcoholic fatty liver disease. N Engl J Med 2002;346(16):1221-1231.
Neuschwander-Tetri BA. Fatty Liver, Non-alcoholic Steatohepatitis. In: Couchman R, Bowler K, editors. ComprehensiveClinicalHepatology.2ed.Elsevier;2006. p.327-40.
Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D,DinaL.Prevalenceandassociatedriskfactorsofnon- alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis2008;17(3):255-260.
Mahady SE, George J. Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism2016;65(8):1172-1182.
AsrihM,JornayvazFR.Dietsandnonalcoholicfattyliver disease: the good and the bad. Clin Nutr 2014;33(2):186- 190.
Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, et al. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem2007;18(3):184-195.
LoriaP,Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, Fargion S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liverdisease: A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010;42(4):272-282.
McCarthy EM, Rinella ME. The role of diet and nutrient composition in nonalcoholic fatty liver disease. J Acad Nutr Diet2012;112(3):401-409.
Anty R, Marjoux S, Iannelli A, Patouraux S, Schneck A-S, Bonnafous S, et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatricsurgery.J Hepatol 2012;57(5):1090-1096.
Birerdinc A, Stepanova M, Pawloski L,YounossiZ. Caffeineisprotectiveinpatientswithnon-alcoholicfatty liver disease. Aliment Pharmacol Ther2012;35(1):76-82.
CatalanoD,MartinesGF,TonzusoA,PirriC,TrovatoFM, Trovato GM. Protective role of coffee in non-alcoholic fattyliverdisease(NAFLD).DigDisSci2010;55(11):3200- 3206.
ModiAA,FeldJJ,ParkY,KleinerDE,EverhartJE,LiangTJ, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010;51(1):201- 209.
MolloyJW,Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee andcaffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012;55(2):429-436.
Zelber-Sagi S, Salomone F,WebbM, Lotan R,YeshuaH, Halpern Z, et al. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Transl Res2015;165(3):428-436.
FeldJJ, Lavoie ÉG, Michel F, Dranoff JA. I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Res2015;4:95.
DayCP,James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology1998;114(4):842-845.
Mikolasevic I, Milic S,WensveenTT,Grgic I, Jakopcic I, Stimac D, et al. Nonalcoholic fatty liver disease-A multisystem disease?WorldJ Gastroenterol 2016;22(43):9488-9505.
Fulgoni VL, Keast DR, Lieberman HR. Trends in intake and sources of caffeine in the diets of US adults: 2001- 2010. Am J Clin Nutr2015;101(5):1081-1087.
EvattDP,Griffiths RR. Caffeine. Encycl Hum Nutr 2013;2:221-227.
McLellan TM, Caldwell JA, Lieberman HR. A review of caffeine’seffectsoncognitive,physicalandoccupational performance. Neurosci Biobehav Rev2016;71:294-312.
Tran N, Barraj L, Bi X, Jack M. Trends and patterns of caffeine consumption among US teenagers and young adults, NHANES 2003–2012.FoodChem Toxicol 2016;94:227-242.
RevelleW,Condon DM, Wilt J. Caffeine. In: RamachandranVS,editor.2ed.EncyclopediaofHuman Behavior: Academic Press; 2012. p.423-39.
de Mejia EG, Ramirez-MaresMV.Impact of caffeine and coffee on our health. Trends Endocrinol Metab 2014;25(10):489-492.
Ahluwalia N, Herrick K, Moshfegh A, Rybak M. Caffeine intake in children in the United States and 10-y trends: 2001–2010. Am J Clin Nutr2014;100(4):1124-1132.
Türkiye Beslenme ve Sağlık Araştırması (TBSA)2010. T.C. Sağlık Bakanlığı, Ankara: 2014.
Köksal E, Yardımcı H, Kocaadam B, Deniz Güneş B, Yılmaz B, Karabudak E. Relationship between dietary caffeine intake and blood pressure in adults. Int JFoodSci Nutr2017;68(2):227-233.
NawrotP,Jordan S, Eastwood J, Rotstein J, Hugenholtz A,FeeleyM. Effects of caffeine on human health.FoodAddit Contam2003;20(1):1-30.
Rotstein J, Barber J, Strowbridge C, Hayward S, Huang R, Godefroy SB. Energy drinks: an assessment of the potential health risks in the Canadian context. IntFoodRisk Anal J2013;3(5):1-29.
TetensI.EFSANDAPanel(EFSAPanelonDietetic Products, Nutrition and Allergies), 2015. Scientific Opinion on the Safety of Caffeine. EFSA Journal 2015;13(5).
Health Canada. Caffeine inFood.February 2, 2012.Availableat:http://www.hc-sc.gc.ca/fn-an/securit/addit/caf/food-caf-aliments-eng.php Accessed June 5,2018
Casiglia E, SpolaoreP,Inocchio G, Ambrosio B. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol1993;9(3):293-297.
Honjo S, Kono S, ColemanMP,Shinchi K, SakuraiY,Todoroki I, et al. Coffee drinking and serum gamma- glutamyltransferase: an extended study of Self-Defense Officials of Japan. Ann Epidemiol1999;9(5):325-331.
Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology2005;128(1):24-32.
Ruhl CE, Everhart JE. Coffee and tea consumption are associatedwithalowerincidenceofchronicliverdisease intheUnitedStates.Gastroenterology2005;129(6):1928- 1936.
Marventano S, Salomone F, Godos J, Pluchinotta F, Del Rio D, Mistretta A, et al. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. Clin Nutr2016;35(6):1269-1281.
Saab S, Mallam D, Cox GA, Tong MJ. Impact of coffee on liver diseases: a systematicreview.Liver Int 2014;34(4):495-504.
Chen S, Teoh NC, Chitturi S, Farrell GC. Coffee and non-alcoholic fatty liver disease: Brewing evidence for hepatoprotection? J GastroenterolHepatol 2014;29(3):435-441.
Gutiérrez-GrobeY,Chávez-Tapia N, Sánchez-ValleV,Gavilanes-Espinar JG, Ponciano-Rodríguez G, Uribe M, et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol2012;11(3):350-355.
BambhaK,WilsonLA,UnalpA,LoombaR,Neuschwander- Tetri BA, Brunt EM, et al. Coffee consumption in NAFLD patients with lower insulin resistance is associatedwith lower risk of severe fibrosis. Liver Int 2014;34(8):1250- 1258.
ShinJW,WangJH, Kang JK, Son CG. Experimental evidencefortheprotectiveeffectsofcoffeeagainstliver fibrosis in SD rats. J SciFoodAgric2010;90(3):450-455.
Gressner OA, Lahme B, Rehbein K, Siluschek M, Weiskirchen R, Gressner AM. Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways. J Hepatol2008;49(5):758-767.
Shim SG, JunDW,Kim EK, Saeed WK, Lee KN, Lee HL, et al. Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model. J Gastroenterol Hepatol2013;28(12):1877-1884.
Poyrazoglu OK, Bahcecioglu IH, Ataseven H, Metin K, Dagli AF, Yalniz M, et al. Effect of unfiltered coffee on carbon tetrachloride-induced liver injury in rats. Inflammation2008;31(6):408-413.
Shen H, Rodriguez AC, Shiani A, Lipka S, Shahzad G, Kumar A, et al. Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis. Therap Adv Gastroenterol2016;9(1):113-120.